Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD8586 in Adult Primary Immune Thrombocytopenia (ITP)
CTR20254731Phase 2Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of birelentinib in immune thrombocytopenia (ITP), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
birelentinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20254731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254731.